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ABSTRACT 
As precision of dosing and patient compliance become an 
important prerequisite for a long-term treatment of Tourette’s 
syndrome there is a need to develop formulation for this drug, 
which overcomes problems such as difficulty in swallowing, 
inconvenience in administration while travelling and patient’s 
acceptability. The present work was undertaken with a view to 
develop a fast dissolving tablets of Pimozide  using Kyron T-314 
as super-disintegrant along with Avicel PH 102 as diluent by 
response surface method using direct compression. Drug-
excipient compatibility studies were confirmed by FTIR 
Spectroscopy. The tablets were evaluated for hardness, friability, 
weight variation, wetting time, disintegration time and 
uniformity of content and in vitro dissolution. Based on 
evaluating parameters, formulation prepared by using 4.5% 
Kyron T-314 with 11.5% Avicel PH-102 was selected as 
optimized formulation and Formulation (F3) had disintegration 
time of 7.63±0.25s and percentage cumulative drug release of   
81.60 after 10min. The formulations were further studied and 
confirmed for their stability. Hence it was concluded that direct 
compression using Kyron T-314 superdisintegrant and Avicel PH 
102 was simple and economic technique which can be used for 
formulation of fast dissolving tablets of Pimozide. 
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INTRODUCTION 
Across a wide variety of disease states, 
recent advances in drug delivery technologies 
have led to the development of innovative 
delivery systems designed to improve therapeutic 
outcome. Emerging delivery platforms for 
improved convenience and adherence with 
psychiatric medications is achieved with fast 
dissolving tablets (FDTs) which are ahead 
among the novel oral drug-delivery systems 
especially in pediatric and geriatric population 
with Dysphagia (Kane et al., 2003).   
Tourette's syndrome is a chronic neuro 
developmental disorder characterized by 
repetitive, stereotyped, involuntary movements 
and vocalizations called tics which have a 
significant impact on patients’ daily functioning 
across many domains. Tics tend to be most 
severe in child and adolescent sufferers, so their 
presence has the potential to impact a period of 
life that is both critical for learning and is often 
associated with the experience of greater social 
tension and self-consciousness than adulthood. 
Furthermore, control over tics that lead to 
physical impairment or self-injurious behavior 
is vital importance in maintaining of health and 
quality of life (James et al., 2002).  
Pimozide is an orally active antipsychotic 
agent of the diphenyl-butylpiperidine series 
indicated for the suppression of motor and 
phonic tics in patients with Tourette's 
syndrome who have failed to respond 
satisfactorily to the standard treatment          
(Clare et al., 2011). Pimozide also has less 
potential for inducing sedation and 
hypotension as it has more strong and specific 
dopamine receptor blocking activity upon            
the post synaptic dopamine receptor than  
other neuroleptic agents and therefore a 
suitable alternative to haloperidol               
(Seemen 2002). Pimozide has an elimination 
half-life of 55h and undergoes hepatic 
metabolism and has about 40-50% bio-
availability   (Fog, 1980; Logan et al.,    1982).  
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The solubility of pimozide in water is less than 
0.01mg/mL; slightly soluble in most organic 
solvents.   
Fast dissolving tablets combines the 
advantages of both liquid and conventional 
tablet formulations, while also offering advan-
tages over both traditional dosage forms like 
enhanced bioavailability, avoidance of first pass 
hepatic metabolism and convenience .Various 
techniques used in formulating FDTs include 
Molding Moulding (Habib et al., 2000), Spray 
drying (Biradar et al., 2006) Mass extrusion, 
Sublimation, Direct compression, Freeze drying 
/lyophilization, Cotton candy process (Reddy et 
al., 2002., Khalid et al., 2011), Phase transition 
techniques (Sadhana et al., 2013)  etc. Direct 
compression technique (Dobetti et al., 2001) 
utilizes conventional equipment, commonly 
available excipients and a limited number of 
processing steps makes this the easiest process 
to manufacture FDTs. High doses can be 
accommodated and the final weight of the tablet 
can easily exceed that of other production 
methods. Kyron T-314 is a novel polacrillin 
potassium superdisintegrants derived from 
cross linked polymer of Polycarboxylic acids as 
per USP/NF & has the K+ ionic form. It is a 
very high purity polymer used in pharmaceutical 
formulations as a super-fast disintegrants as 
well as dissolution improver in solid dosage 
forms like tablets, capsules, pellets etc 
(Chaudary et al., 2005).  Acry flow-L is chemically 
poly 12-hydroxy stearate widely used in oral 
dosage formulations as an excellent tablet 
lubricant.  It is high molecular weight polymer 
and does not get absorbed by body tissue and 
hence safe for human consumption and hence 
has no physiological action at recommended 
dosage (Bi et al., 1995). 
An attempt has been made to develop 
fast dissolving tablets of pimozide with a novel 
superdisintegrant Kyron T-314 using response 
surface method by direct compression method. 
Based on the preliminary studies, the ranges for 
the formulations were selected, the response 
(dependent) variables being Disintegration time 
(DT). 
 
MATERIAL AND METHODS 
Pimozide was gifted by Vasudha Pharma 
Chem Pvt Ltd, Hyderabad. Kyron T314 and 
Acry flow L were obtained as gift samples from 
Corel Pharma Chem., (Ahmedabad, India). All 
other chemicals and reagents used were of 
analytical grade and used as supplied by the 
manufacturer. 
 
Experimental design 
Solubility study of pimozide 
Solubility studies of pimozide                 
were carried out in 0.01N HCl, acetate buffer 
pH 4.5, phosphate buffer pH 6.8,               
phosphate buffer pH 7.2 and distilled  water.  
Table I. Level of formulation variables 
 
 Name Units Low  High -alpha +alpha 
A [Numeric] 
B [Numeric] 
Kyron T-314 
Avicel PH 102 
mg 
mg 
9 
12 
15 
23 
7.75736 
9.72183 
16.2426 
25.2782 
 
Table II. Formulation of FDTs of pimozide 
 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 
Pimozide 1 1 1 1 1 1 1 1 1 
Kyron T-314 9 9 9 12 12 12 15 15 15 
Avicel PH 102 12 17 23 12 17 23 12 17 23 
Mannitol 171 166 160 168 163 157 165 160 154 
Acryflow-L 3 3 3 3 3 3 3 3 3 
Talc 4 4 4 4 4 4 4 4 4 
Total weight 200 200 200 200 200 200 200 200 200 
 
1 and 3 shows CSF3syn.Ec3 as restriction product D. Colony PCR of BL21(DE3)_pET32a(+)_CSF3syn.Ec3 
with R- and F- insert gene primers. M = 1 kb DNA Marker; NC = negative control; PC = positive control or 
recombinant plasmid pET32a(+)_CSF3syn.Ec3 
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A sample of 20mg of pure pimozide was taken 
in 15mL screw cap test tubes containing 10mL 
of media. The solutions were shaken and kept 
aside for 24h with continuous stirring. After 
24h, the sample solutions were filtered through 
Whatmann filter paper which a filtrate of 1mL 
was diluted to a suitable concentration with 
respective buffer media. The absorbance of the 
prepared dilutions were measured at 278nm 
using UV-Visible spectrophotometer. The 
results were tabulated as shown in table III 
 
Experimental design 
The present study involved Response 
Surface Method with 2 factors as shown in 
table I. Experimental trials were performed as 
shown in table II. 
 
Formulation of fast dissolving tablets  
FDTs were prepared by direct 
compression method. Nine different 
formulations were prepared  using Kyron T 314 
as a superdisintegrants and Avicel PH 102 as 
diluent. All the ingredients (Pimozide, mannitol, 
Avicel pH 102), except Acry flow L and Talc 
were passed through 60 mesh size separately 
and mixed. Then Acry flow L and Talc as 
Lubricant and Glidant respectively were added 
and compressed into tablet using 8mm punch 
on rotary tablet compression machine. Table II 
show the formulation of FDTs of Pimozide. 
 
Evaluation of FDTs 
The FDTs were studied further for 
chemical interaction using Infra-red 
Spectroscopy. The results were shown in 
figures 1 and 2 and table IV. 
 
Evaluation of pre-compression 
parameters 
The prepared powder tablet blend was 
evaluated for their pre-compression parameters 
including bulk density (Db), tapped density (ρt), 
Carr’s compressibility index (I), Hausner ratio 
(H) and Angle of Repose (θ). The results were 
shown in table V. 
 
Evaluation of post-compression 
parameters 
FDTs were evaluated for post-
compression parameters like weight variation, 
Hardness, Friability, and thickness. The results 
were tabulated as shown in table VI. 
Wetting time and water absorption 
ratio 
Wetting time and water absorption ratio 
were calculated by taking a piece of tissue paper 
of internal diameter 6.5cm was folded twice 
and placed in a small petri dish containing 6mL 
of water. A tablet was put on the middle of the 
paper, and the time for complete wetting was 
measured. The wetted tablet was reweighed to 
calculate the water absorption ratio was 
calculated by the following formula: 
R=100×(Wa -Wb )/Wa 
Where Wa is weight of tablet after water 
absorption and Wb is weight of tablet before 
water absorption. Three trials for each batch 
were performed and standard deviation was 
also determined. 
 
In vitro dispersion time 
The study was conducted by                
placing a tablet in a beaker containing 10mL          
of  pH 6.8 buffer at 37±0.5º and the time 
required for complete dispersion was 
determined. 
 
Drug content uniformity  
The content uniformity was determined 
by Placing a tablet in a 50mL round-bottomed 
flask (RBF), add 5mL of 0.1N HCl, and shaken 
by mechanical stirrer for 30min to which 20mL 
of methanol was added and shaken for 20 more 
minutes. Dilutions with methanol were made to 
obtain a solution having a concentration of 
about 40μg of Pimozide per mL, mixed 
centrifuged at 1000rpm. Concomitantly, the 
absorbance of the solution of Pimozide was 
observed at 277nm, using a double beam UV-              
Visible spectrophotometer (TDT-08L,  
Electrolab, India), against methanol as a             
blank. Further the drug content was         
measured using the formula as below: (TC/D) 
(AU/AS) 
Where ‘T’ is the labeled quantity of 
Pimozide (in mg) in the Tablet, ‘C’ is the 
concentration, in µg per mL, of Pimozide in the 
Standard solution, ‘D’ is the concentration, in 
µg/mL, of Pimozide in the solution from the 
tablet.  
‘AU’ and ‘AS’ are the absorbance of the 
solution from the tablet and the Standard 
solutions respectively. 
Raja Rajeswari Kamisetti 
Volume 26 Issue 2 (2015) 117 
In vitro disintegration time 
In vitro disintegration test was carried out 
in USP tablet disintegration apparatus by 
placing one tablet in each of the 6 tubes of the 
basket containing pH 6.8 phosphate buffer as 
medium maintained at 37±2oC. The time 
required in seconds for the complete 
disintegration of the tablet with no visible mass 
remaining in the apparatus was measured and 
recorded. The results of wetting time, in vitro 
dispersion time, drug content uniformity and in 
vitro disintegration time were shown in table 
VII. 
 
In vitro dissolution studies 
In vitro dissolution studies were carried 
out in USP Type II paddle apparatus (Lab 
India, India) maintained at 37±0.5°C using 
900mL of phosphate buffer pH 6.8 as the 
dissolution medium at 50rpm. Aliquots of             
the samples were collected at specified            
time  intervals  and were replaced with the fresh  
medium after each withdrawal. The samples 
were observed for their respective absorbances 
at 277nm by UV spectrometry and their 
cumulative percentage drug release was 
calculated (Figure 3 and 4). 
 
Table III. Solubility behavior of pimozide 
 
Buffers Absorbance Concentration ( mg/mL) 
0.01 N HCl 0.255 0.023091 
4.5 pH 0.241 0.021818 
6.8 pH 0.196 0.017727 
7.2 pH 0.130 0.011727 
H2O 0.079 0.007118 
 
 
 
Figure 1. IR Spectra of pimozide. 
 
 
 
 Figure 2. IR Spectra of pimozide and physical mixture with excipients. 
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Stability studies 
Short-term stability studies on the 
promising formulations (F3) were carried out 
by storing the tablets in an amber coloured 
rubber stoppered vial at 40º/75% RH for           
3 months.   At an interval of 1 month, the 
tablets were visually examined for any physical 
changes, changes in drug content and in vitro 
dispersion time. 
RESULTS AND DISCUSSION 
Solubility studies showed distinct 
solubility of Pimozide very poor solubility in 
distilled water and moderate solubility in 
buffers of pH 7.2 and 6.8. The drug was found 
to have better solubility in 0.01N H Cl and 
buffer of  pH 4.5 (Table III). The results 
indicate that there were no possible chemical 
interactions between the drug and the  
Table IV. Drug-excipient interactive studies. 
 
NO 
Wave number in formulation (cm-1) Characteristic 
wave number 
range (cm-1) 
Bond nature and bond 
attributed Pure drug 
Optimized 
formulation 
1 
2 
3 
4 
5 
 
6 
3219.42 
1697.36 
1635.29 
1507.89 
1223.23 
 
692.11 
3281.91 
1697.08 
1639.31 
1511.85 
1250.52 
 
693.93 
3400-3250 
1640-1690 
1550-1640 
1400-1600 
1000-1400 
 
690-710 
N-H  stretching 
C=O stretching(amines) 
N-H  bending (amines) 
C=H stretching in Aromatics. 
C-F   strong stretching Mono 
substituted cycloalkane 
C-H  deformation 
 
TableV. Evaluation of pre-compression parameters of fast dissolving tablets 
 
Formulation 
code 
Bulk density 
(gm/cc) 
Tapped density 
(gm/cc) 
Angle of repose 
(degrees) 
Carr's index 
(%) 
Hausner 
ratio 
F1 0.48±0.12 0.58±0.10 27.47±0.11 17.241±0.11 1.208±0.11 
F2 0.47±0.10 0.57±0.10 24.70±0.11 17.544±0.12 1.213±0.12 
F3 0.46±0.13 0.57±0.10 26.59±0.10 19.298±0.10 1.239±0.10 
F4 0.49±0.11 0.59±0.11 26.54±0.13 16.949±0.14 1.204±0.13 
F5 0.47±0.11   0.6±0.10 25.64±0.11 21.667±0.10 1.277±0.10 
F6 0.47±0.11 0.59±0.12 25.41±0.13 20.339±0.1 1.255±0.22 
F7 0.45±0.13 0.57±0.14 24.70±0.10 21.053±0.11 1.267±0.11 
F8 0.47±0.11 0.59±0.13 25.61±0.10 20.339±0.12 1.255±0.11 
F9 0.46±0.11 0.56±0.11 23.79±0.12 17.857±0.11 1.217±0.13 
 
Table VI. Evaluation of post-compression parameters of fast dissolving tablets 
 
Formulation 
code 
Hardness + 
SD (kg/cm2) 
Friability (%) Thickness 
(mm) 
Weight variation 
+ SD (mg) 
F1 3.05±0.53 0.55±0.15 2.97±0.058 197.43±2.23 
F2 3.12±0.121 0.56±0.11 2.92±0.053 199.14±2.91 
F3 3.11±0.102   0.4±0.11 2.93±0.061 197.57±2.3 
F4 3.09±0.091 0.51±0.12 2.98±0.075 197.14±2.19 
F5 3.15±0.139 0.85±0.11 2.96±0.036 196.71±1.98 
F6 3.14±0.131   0.6±0.11 2.87±0.08 197.43±2.15 
F7 3.13±1.125 0.66±0.15 2.92±0.045 196.86±2.04 
F8 3.12±0.122 0.72±0.11 2.93±0.070 198.57±2.07 
F9 3.16±0.077 0.65±0.11 2.90±0.042 198.43±2.76 
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Table VII. Evaluation of post-compression parameters of fast dissolving tablets 
 
Formulation Code 
Wetting time 
+ SD (Sec) 
Disintegration 
time + SD (Sec) 
% Drug 
content 
F1 15.5±0.66 8.30±0.19 98.43±0.98 
F2 15.4±0.44   9.4±0.26 97.37±1.4 
F3 14.5±0.35 7.63±0.25 99.10±1.97 
F4 16.8±0.36   8.6±0.30 98.90±1.9 
F5 17.3±0.46          10.48±0.3 98.33±2.61 
F6 16.6±0.53 9.36±0.25 98.33±2.61 
F7 17.3±0.60     9.7±0.26 96.10±1.37 
F8 20.9±0.56 10.8±0.53 97.57±1.22 
F9 21.2±0.36 10.9±0.20 97.23±1.5 
 
 
 
 Figure 3. Invitro dissolution profile of FDTs of Pimozide 
 
 
 
Figure 4. Contour plot of FDTs of pimozide 
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excipients (Figure 1, 2 and Table IV). The pre-
compression parameters were found to within 
the specified limits and show on table V. The 
results of evaluation post-compression 
parameters were found to be within the limits 
(Table VI and VII)  
 
In vitro dissolution time profile 
Optimization 
The Model F-value of 16.56 implies           
the model is significant. There is only a           
0.09% chance that an F-value this large could 
occur due to noise. Values of "Prob> F" less 
than 0.0500 indicate model terms are 
significant.  
The optimization model was found to be 
significant with F value 33.32 and p-value of 
0.0027. It was found that disintegration time 
increased with an increase in the concentration 
of Kyron T 314. Formulation F 3 got 
disintegrated in 7.63s. Hence it was concluded 
that Formulation F3 was optimized. 
 
Stability studies 
Accelerated stability studies on the 
promising formulations (F3) were found to 
have physical stability without any 
morphological changes and the drug content 
was found to be within the limits.  
 
CONCLUSION 
Hence it has been concluded that Design 
of Experiments following Response Surface 
Methodology can be effectively used in the 
design, formulation and evaluation of FDTs of 
drugs. By adopting a systematic formulation 
approach (DOE-RSM), an optimum point can 
be reached in the shortest time with minimal 
efforts. Pimozide fast dissolving tablets can be 
successfully prepared using Kyron T-314 as 
superdisintegrant which effectively reduces the 
disintegration time and thus enhance patient 
compliance. 
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